Comparison of Bridge-to-Transplant Outcomes with HeartMate 3 and HeartMate II Left Ventricular Assist Devices: A UNOS Registry Analysis

The Momentum 3 trial established the noninferiority of the HeartMate 3 (HM3) left ventricular assist device (LVAD) compared to HeartMate II (HM2) for survival free of disabling stroke or need for surgical intervention due to LVAD malfunction- leading to FDA approval of HM3 for bridge-to-transplant (BTT) and destination therapy. Heart transplant (HT) waitlist outcomes have not specifically been compared between HM3 and HM2.

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: R.C. Givens, S.M. Kochav, P.C. Colombo, M.A. Farr, S.W. Restaino, V.K. Topkara Tags: 868 Source Type: research